SPY381.42-5.12 -1.32%
DIA312.99-1.20 -0.38%
IXIC12,997.75-361.04 -2.70%

DJ Regeneron Says Barriers for Covid-19 Drug Persist -- Market Talk

· 02/05/2021 10:00

0959 ET - Regeneron continues to see barriers to patients getting its Covid-19 antibody drug, both in doctors prescribing it and in allowing people to easily get it when it is prescribed, says CEO Leonard Schleifer on 4Q earnings call. "We need to do work at all ends of the funnel," he says, but things are starting to get better. In some cases, medical-record algorithms are alerting doctors that their patients are eligible to take the drug after testing positive and meeting certain-risk factor requirements, says Dr. Schleifer. But some doctors who are aware of the drugs remain skeptical that there isn't yet enough data to support its use, he says. Regeneron shares gain 0.7% on the day, but are 19% lower over the past six months. (joseph.walker@wsj.com)

(END) Dow Jones Newswires

February 05, 2021 10:00 ET (15:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.